MiR-29c was found to target the classical anti-apoptotic proteins B cell lymphoma 2 (Bcl-2) family including myeloid cell leukemia 1 (MCL1) and Bcl-2 itself in human NPC. Here, MCL1 is linked to nasopharyngeal carcinoma.